Filter Results:
(5,199)
Show Results For
- All HBS Web
(5,199)
- People (17)
- News (2,070)
- Research (2,508)
- Events (2)
- Multimedia (223)
- Faculty Publications (1,868)
Show Results For
- All HBS Web
(5,199)
- People (17)
- News (2,070)
- Research (2,508)
- Events (2)
- Multimedia (223)
- Faculty Publications (1,868)
- June 1999 (Revised May 2000)
- Case
EndoSonics
EndoSonics is a manufacturer of a sophisticated medical device--a catheter that can take ultrasonic images within the blood vessels of the heart. The company deals with a series of challenges that relate to implementing a difficult technology in the face of a complex... View Details
Keywords: Information Technology; Distribution; Decision Choices and Conditions; Corporate Strategy; Entrepreneurship; Health Care and Treatment; Problems and Challenges; Manufacturing Industry; Medical Devices and Supplies Industry
Roberts, Michael J., and Diana S. Gardner. "EndoSonics." Harvard Business School Case 899-262, June 1999. (Revised May 2000.)
- 04 Mar 2014
- News
40 of the Smartest People in Healthcare
- June 1994 (Revised March 1995)
- Case
Lotus Development Corp.: Spousal Equivalents (A)
A group of Lotus employees propose extending all health care and other benefits to the spousal equivalents of lesbian and gay employees. The vice president of human resources considers the proposal during a reorganization and period of financial uncertainty. View Details
Gentile, Mary C., and Sarah Gant. "Lotus Development Corp.: Spousal Equivalents (A)." Harvard Business School Case 394-197, June 1994. (Revised March 1995.)
- 16 Jun 2020
- Research & Ideas
Your Customers Have Changed. Here's How to Engage Them Again.
than recent economic crises and recessions such as the Great Recession of 2008 and the Mideast oil crisis, whose causes were financially driven. The fundamental driver of the pandemic is health and safety concerns and hence customer... View Details
- April 2023
- Article
Performance on Patient Experience Measures of Former Chief Medical Residents as Physician Exemplars Chosen by the Profession
By: Lucy Chen and J. Michael McWilliams
OBJECTIVE To compare care for patients of primary care physicians (PCPs) who were former chiefs with care for patients of nonchief PCPs.
DESIGN, SETTING, AND PARTICIPANTS Using 2010 to 2018 Medicare Fee-For-Service Consumer Assessment of Healthcare... View Details
DESIGN, SETTING, AND PARTICIPANTS Using 2010 to 2018 Medicare Fee-For-Service Consumer Assessment of Healthcare... View Details
Keywords: Performance Evaluation; Forecasting and Prediction; Knowledge Use and Leverage; Competency and Skills; Surveys; Health Industry
Chen, Lucy, and J. Michael McWilliams. "Performance on Patient Experience Measures of Former Chief Medical Residents as Physician Exemplars Chosen by the Profession." JAMA Internal Medicine 183, no. 4 (April 2023): 350–359.
- 23 Jan 2020
- News
Five Ways Hospitals Will Change in Next Decade
- 07 Jun 2014
- Video
Ebru Dorman - Making A Difference
- Article
One Obstacle to Curing Cancer: Patient Data Isn't Shared
By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
- February 2015 (Revised November 2015)
- Supplement
Building an Integrated Biopharma Company: Crucell (B)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling
The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Pharmaceutical Industry
Hamermesh, Richard G., Marianne Van Der Steen, and Susan Harmeling. "Building an Integrated Biopharma Company: Crucell (B)." Harvard Business School Supplement 815-086, February 2015. (Revised November 2015.)
- 03 May 2022
- Cold Call Podcast
Can a Social Entrepreneur End Homelessness in the US?
Keywords: Re: Brian L. Trelstad
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
Vogel, Matthew, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim, and Benjamin N. Rome. "Cost of Exempting Sole Orphan Drugs from Medicare Negotiation." JAMA Internal Medicine 184, no. 1 (January 2024): 63–69.
- 24 Jan 2017
- First Look
First Look at New Research: January 24, 2017
Yoshimi Anzai, Marta E. Heilbrun, Derek Haas, Luca Boi, Kirk Moshre, Satoshi Minoshima, and Vivian S. Lee Abstract—The lack of understanding the true costs (not charges) of delivering health care services... View Details
Keywords: Sean Silverthorne
- 27 Nov 2017
- News
Payment Reform Is a Play We’re All Watching
- 03 Feb 2015
- Working Paper Summaries
Regulator Leniency and Mispricing in Beneficent Nonprofits
- 24 Apr 2019
- News